Astellas' SGLT2 inhibitor meets Phase III endpoints in diabetes

Astellas Pharma Inc. (Tokyo:4503) said ipragliflozin met the primary endpoint in two Phase III trials to treat Type II diabetes. A Japanese trial in 151 patients with inadequate glycemic control on pioglitazone showed that once-daily ipragliflozin as an add-on to pioglitazone significantly reduced HbA1c from baseline to week 24 vs. placebo (0.64% vs. a 0.22% increase, p<0.001). ...